🧫
Recurrent UTI — Assessment & ManagementUrosepsis 999 · haematuria 2WW · MSU culture · topical oestrogen · D-mannose · methenamine · self-start · prophylaxis · NICE NG112
Progress0 / 9
The full reasoning pathway — confirm recurrent UTI with cultures, exclude underlying causes and red flags, then use prevention strategies before long-term antibiotics. Safety-net.StartDecisionInvestigateActionReferStop / Admit
PresentationRecurrent UTI
≥2 in 6 months or ≥3 in a year. Confirm with cultures; LUTS, post-coital pattern, menopausal status; exclude incomplete emptying.
Step 1 · Safety — structural cause / red flagsStructural cause or red flags?
Persistent haematuria (NG12 thresholds), recurrent same-organism infection, stones, obstruction, or men/children (always investigate).
YES
Stop · Escalate2WW / investigate
Persistent haematuria → 2WW. Men/children/structural concern → urology + imaging.
NO
AssessBy pattern
History + examination localise the cause.
Step 7 · prevention & management
Prevention first
Self-care
Hydration, post-coital voiding; vaginal oestrogen in postmenopausal women; consider methenamine.
Antibiotic strategies
If needed
Stand-by or post-coital antibiotic; antibiotic prophylaxis as last resort with review.
Investigate cause
Assess
Post-void residual, imaging if indicated; exclude diabetes, stones.
Step 6 · ReferEscalation
2WW persistent haematuria. Urology men, recurrent same-organism, structural concern, or failure of prevention; always investigate UTI in men and children.
Step 8 · prevention & self-management
Step 8 · Prevention & self-management (first-line)Try before long-term antibiotics
Good hydration, regular and post-coital voiding, avoid spermicide/diaphragm if relevant, wipe front-to-back, treat constipation. Vaginal oestrogen in postmenopausal women (powerful, underused) and consider methenamine hippurate or D-mannose; optimise glycaemic control in diabetes. Reserve stand-by/post-coital or low-dose prophylactic antibiotics for failure of these measures, with review.
Step 9 · review & safety-net
Step 9 · Review & safety-netReassess & spot the red flags
Review prophylaxis (e.g. 6-monthly) for ongoing need, efficacy and resistance; re-culture breakthrough infections. 2WW for visible (or unexplained non-visible at NG12 thresholds) haematuria; investigate / refer all UTIs in men and children, recurrent same-organism infection, or suspected stones/obstruction/incomplete emptying. Same-day if systemically unwell (pyelonephritis/sepsis).
⚠️ Vaginal oestrogen is a powerful, underused preventive in postmenopausal women — try prevention strategies before committing to long-term prophylactic antibiotics.
1
Safety

Red Flags — Urosepsis, Malignancy & Structural Cause

Recurrent UTI (2+ in 6 months or 3+ in 12 months) requires investigation. Urosepsis is a medical emergency. Macroscopic haematuria requires its own 2WW investigation — never attribute haematuria to infection alone.

UTI + fever >38°C + rigors + loin pain + haemodynamic instability Urosepsis / ascending pyelonephritis with bacteraemia. → 999 if BP <90/60, HR >100, or confused. IV antibiotics (ceftriaxone + gentamicin if severe). Blood cultures before antibiotics. All systemically unwell = hospital.
Recurrent UTI + macroscopic haematuria + age >45 or smoker Urothelial cancer — bladder TCC or SCC. 2WW urology immediately. Treat UTI AND refer 2WW simultaneously. Never assume haematuria is explained by infection. NICE NG12.
Recurrent UTI + new neurological symptoms + lower limb weakness or incontinence Neurogenic bladder from spinal cord pathology → high urosepsis risk. MRI spine urgently.
UTI in a male under 65 without catheter or known structural cause UTI uncommon in young men — structural cause until excluded. STI screen (GC/Chlamydia). USS urinary tract. Urology referral.
Pyelonephritis not responding to 48h IV antibiotics in a diabetic Emphysematous pyelonephritis (gas-forming E. coli/Klebsiella — surgical emergency). CT abdomen urgently. Hospital.
Recurrent UTI + poor urinary stream + hesitancy + incomplete emptying Bladder outflow obstruction (BPH, stricture, cystocoele, neurogenic). Post-void residual USS — >100 ml = significant. Urgent urology.
Haematuria-UTI conflation is one of the most common pathways to delayed bladder cancer diagnosis — haematuria attributed to UTI, infection treated, haematuria appears to resolve, no investigation arranged. NICE NG12: any unexplained macroscopic haematuria in an adult = 2WW urology, regardless of concurrent UTI. Treat the UTI AND refer 2WW simultaneously. Bladder cancer frequently co-presents with UTI (blood in bladder + stasis = bacterial growth). Emphysematous pyelonephritis: gas-forming organisms (E. coli, Klebsiella) in diabetics produce CO₂ within renal parenchyma — necrotising infection with mortality 40–90% without surgery. Any diabetic not improving on IV antibiotics at 48 hours = CT abdomen urgently.
2
Diagnose

Classification — Causes of Recurrent UTI

Host factors
Post-menopausal status (oestrogen deficiency → vaginal atrophy → loss of Lactobacillus → ascending E. coli) · Sexual activity (mechanical urethral inoculation) · Spermicide use (disrupts vaginal flora) · Poor fluid intake + infrequent voiding · Constipation (faecal reservoir) · Diabetes (glycosuria + impaired neutrophil function) · Genetics (P blood group antigen — UPEC adhesion)
Structural / anatomical
Incomplete bladder emptying (BPH, urethral stricture, cystocoele, neurogenic bladder — residual urine = bacterial growth medium) · Vesicoureteric reflux · Renal calculi (struvite/infection stones — harbour bacteria, never clear without stone removal) · Colovesical fistula (pneumaturia + mixed faecal organisms — diverticular disease or Crohn's)
Bacterial factors
UPEC (E. coli) 80–85%. Proteus mirabilis (urease-producing → alkaline urine → struvite stones). Relapse (same organism <2 weeks) = inadequate treatment or structural source. Reinfection (different organism or >2 weeks) = re-ascent from periurethral/bowel reservoir.
Drug-induced
SGLT2 inhibitors (pharmacological glycosuria → increased UTI susceptibility) · Immunosuppressants
Relapse vs reinfection: relapse (same organism within 2 weeks) suggests inadequately treated infection or structural source maintaining bacterial persistence (calculus, prostate, stricture) → structural investigation. Reinfection (different organism or >2 weeks) suggests re-ascent — most common pattern in women. Struvite stones: any recurrent UTI consistently growing Proteus mirabilis = renal imaging (USS + KUB X-ray / CT) to exclude struvite/staghorn calculus. Cannot eradicate with antibiotics alone — stone removal required for cure. Colovesical fistula: pneumaturia (gas in urine — bubbles on voiding) + recurrent mixed-organism UTI (E. coli + Enterococcus + anaerobes) in older male with diverticular disease = CT abdomen/pelvis for diagnosis.
3
Diagnose

Assessment & Investigations

History
Episode frequency + organisms (same = relapse; different = reinfection) · Precipitating factors (post-coital?) · Fluid intake · Voiding pattern (holds urine? Post-void dribbling? Pneumaturia?) · Post-menopausal status + vaginal symptoms · Sexual history + contraception (spermicide use?) · Catheter · Diabetes · Previous investigations · Family history
Examination
Loin tenderness (pyelonephritis) · Suprapubic tenderness, palpable bladder (retention) · Women: urethral prolapse, cystocoele (anterior vaginal wall descent = incomplete emptying), vaginal atrophy (pale thin dry mucosa) · Men: PR if prostatitis (tender prostate — no vigorous massage → bacteraemia risk)
Investigations
MSU culture all episodes — document organism + sensitivity each time (essential for relapse vs reinfection pattern) · Renal + bladder USS (post-void residual, hydronephrosis, stones, bladder lesion) · HbA1c (diabetes) · eGFR + U&E · Flexible cystoscopy (macroscopic haematuria, male recurrent UTI, female >50 with recurrent UTI) · Urine cytology (atypical cells)
Do NOT treat asymptomatic bacteriuria
Non-pregnant adults: NICE NG112 — treating ABU does not reduce symptomatic UTI and increases AMR. Elderly: positive MSU + non-specific symptoms (confusion, falls) ≠ UTI — investigate the actual cause. Treat ONLY if: pregnant, pre-urological procedure, renal transplant (first 2 months), or symptoms are genuinely specific (dysuria, frequency, suprapubic pain).
Asymptomatic bacteriuria (ABU) in elderly women affects 10–25% of community-dwelling women over 70 — it is a normal finding and does NOT require treatment (NICE NG112). The most common prescribing error in primary care and care homes is treating a positive MSU in an elderly woman with non-specific symptoms as a UTI. NHSEngland Patient Safety Alert (2016) specifically warns against this. Pregnancy ABU MUST be treated — 30% risk of pyelonephritis without treatment. MSU at booking, treat any positive culture with cefalexin 500 mg TDS × 7 days, test of cure at 7 days + monthly surveillance throughout pregnancy.
4
Diagnose

Risk Stratification & Investigation Triggers

Always investigate further
≥3 culture-proven UTIs in 12 months · ≥2 in 6 months · Any UTI in male under 65 · Macroscopic haematuria → 2WW · Pyelonephritis not resolving in 72h on IV antibiotics · Proteus mirabilis consistently (struvite stone) · Poor stream/hesitancy + UTI · Pneumaturia (colovesical fistula)
Urology referral triggers
Male patient with any UTI · Macroscopic haematuria (2WW) · Post-void residual >100 ml · Stone disease · Bladder cancer suspected (positive cytology) · Not controlled by self-start or prophylaxis at 6 months
ABU — treat only if
Pregnant · Pre-urological procedure (24–48h cover) · Renal transplant (first 2 months) · Symptomatic with specific urinary symptoms
Urine cytology indication
All macroscopic haematuria referrals · Recurrent UTI + smoker >40 + persistent microscopic haematuria · Atypical symptoms suggestive of bladder pathology
Post-void residual USS: values above 100 ml impair the natural bladder flushing defence mechanism (bacteria multiply in stagnant residual urine). Normal <50 ml; borderline 50–100 ml; clinically significant >100 ml. Bladder scanner USS takes 2 minutes — should be part of every recurrent UTI assessment. Any UTI prevention strategy will be less effective while significant residual urine persists. Treat the underlying cause: BPH → alpha-blocker; cystocoele → gynaecology; neurogenic → intermittent self-catheterisation; functional voiding dysfunction → pelvic floor physiotherapy.
5
Refer

Referral Pathways

999 / Same-day
Urosepsis (fever + instability + confusion) · Emphysematous pyelonephritis · Acute urinary retention
2WW urology
Any macroscopic haematuria in adult (concurrent UTI does not remove 2WW obligation) · Recurrent UTI + haematuria + age >45 · Recurrent UTI in male under 65
Urology (urgent 2 weeks)
Post-void residual >100 ml · Stone disease contributing to recurrent UTI · Outflow obstruction symptoms · Not controlled by self-start/prophylaxis at 6 months · Positive urine cytology
Gynaecology
Pelvic organ prolapse (cystocoele — incomplete emptying) · Young women with suspected anatomical variant
Pelvic floor physiotherapy
Voiding dysfunction without structural cause · Pelvic floor weakness + recurrent UTI · Bladder retraining programme
GP management
Post-menopausal: topical oestrogen (first-line). Self-start antibiotics. Post-coital single dose. D-mannose. Methenamine hippurate. Continuous low-dose prophylaxis as last resort.
Topical vaginal oestrogen for post-menopausal recurrent UTI: estriol 0.01% cream (Gynest) 0.5g intravaginally nightly × 2 weeks → twice weekly maintenance; or oestradiol 10 mcg vaginal tablets (Vagifem) same schedule. NNT approximately 3 for preventing ≥1 UTI over 6 months (Raz and Stamm NEJM 1993). SAFE in breast cancer history — negligible systemic absorption (NICE NG196, BMS guidelines confirm safety). Mechanism: restores vaginal Lactobacillus colonisation + acidic pH + periurethral mucosal integrity → reduces E. coli colonisation. Most evidence-based and most underused intervention for post-menopausal recurrent UTI. Offer BEFORE antibiotic prophylaxis.
6
Treat

Acute UTI Treatment

Uncomplicated UTI — women
Nitrofurantoin 100 mg MR BD × 3 days (first-line if eGFR ≥45)
UK E. coli nitrofurantoin resistance <5% — the most microbiome-sparing effective option. Avoid at term. If contraindicated: pivmecillinam 400 mg stat then 200 mg QDS × 3 days. Or trimethoprim 200 mg BD × 3 days (check local resistance data — ~30% E. coli resistance in UK).
UTI in men
Trimethoprim 200 mg BD × 7 days
Men need 7-day courses. MSU culture before starting. STI screen alongside. Ciprofloxacin 500 mg BD × 28 days if prostatitis suspected.
UTI in pregnancy
Cefalexin 500 mg TDS × 7 days
Nitrofurantoin avoid at term. Trimethoprim avoid first trimester. Test of cure (repeat MSU) at 7 days + monthly surveillance. Treat ALL bacteriuria including asymptomatic.
Pyelonephritis — community, well
Ciprofloxacin 500 mg BD × 7 days
Culture before starting. Co-amoxiclav 625 mg TDS × 14 days if ciprofloxacin contraindicated. Hospital (IV ceftriaxone + gentamicin) if vomiting, confusion, or haemodynamic instability.
Nitrofurantoin vs broad-spectrum: UK E. coli nitrofurantoin resistance <5% — it is the most microbiome-preserving effective option (acts locally within urine, minimal gut flora disruption). Trimethoprim UK resistance approximately 25–30% — check local CCG/ICB antibiogram. Co-amoxiclav and cefalexin should be reserved for complicated UTI/pyelonephritis. Pivmecillinam (Selexid): ~5% UK E. coli resistance, narrow spectrum, minimal microbiome disruption — NICE NG112 first-line alongside nitrofurantoin. Pregnancy: treat ALL bacteriuria (asymptomatic or symptomatic) — 30% develop pyelonephritis without treatment. Test of cure mandatory.
7
Treat

Prevention Strategies

Post-menopausal: topical oestrogen (first-line)
Estriol 0.01% cream (Gynest) 0.5g intravaginally nightly × 2 weeks → twice weekly long-term. Or oestradiol 10 mcg vaginal tablets (Vagifem). NNT ~3. Safe even with breast cancer history. Start before antibiotic prophylaxis.
Self-start antibiotics
Protocol: GP provides nitrofurantoin 100 mg MR BD × 3 days. Patient starts at first symptoms, sends MSU within 24h, reports if no improvement at 48h, keeps episode diary. Review at 6 months. Reduces consultation burden + inappropriate antibiotic use.
Post-coital single-dose prophylaxis
Nitrofurantoin 100 mg stat or trimethoprim 200 mg stat within 2h of intercourse. For documented post-coital trigger. RCTs show equivalent efficacy to daily prophylaxis for post-coital UTI pattern. Minimal antibiotic exposure.
D-mannose
2 g OD (or 1 g BD). Blocks type 1 fimbria E. coli adhesion to urothelium. RCT (Kranjcec 2014): equivalent to nitrofurantoin prophylaxis for E. coli UTI prevention. Safe in pregnancy. OTC. Recommend before prescribing continuous antibiotics.
Methenamine hippurate (Hiprex)
1 g BD. Non-antibiotic urinary antiseptic — urinary acidification → formaldehyde release → kills bacteria. Cochrane 2022: significant UTI reduction vs placebo, NNT ~5 over 12 months. No resistance selection. NICE NG112 approved. CI: eGFR <30, gout, urinary alkalinisers (potassium citrate).
Continuous low-dose antibiotic prophylaxis
Nitrofurantoin 50 mg nocte or trimethoprim 100 mg nocte or cefalexin 125 mg nocte × 6 months. Last resort when above fail. Nitrofurantoin >6 months: annual CXR + LFT (pulmonary fibrosis risk ~1:5,000–10,000). Trimethoprim: annual FBC (megaloblastic effect). Review indication at 6 months.
Cranberry (adjunct)
Standardised extract 36 mg PAC OD (not juice — variable PAC content + high sugar). Cochrane: modest UTI reduction, NNT ~8. Safe adjunct but less effective than D-mannose or methenamine.
Bladder optimisation
1.5–2 L fluid daily. Void every 2–3h. Double-void technique. Post-coital voiding within 30 minutes. Constipation treatment. Post-void residual <100 ml target.
Methenamine hippurate deserves emphasis — 2022 Cochrane review (Bonkat et al.) found significant UTI reduction, NNT approximately 5, with NO resistance selection (non-antibiotic mechanism: formaldehyde kills bacteria non-selectively). NICE NG112 approved. Particularly valuable for: women in whom nitrofurantoin is contraindicated (eGFR <45), patients with multidrug-resistant organisms, or when long-term antibiotic use is undesirable. D-mannose: Kranjcec 2014 RCT showed equivalence to nitrofurantoin prophylaxis for E. coli UTI prevention, OTC, safe in pregnancy, excellent safety profile — should be first preventive recommendation before prescribing any antibiotic prophylaxis. Post-coital voiding: flushes periurethral bacteria mechanically within 30 minutes of intercourse — Foxman 1990 showed ~30% UTI reduction in post-coital pattern. Free, simple, effective.
8
Lifestyle

Fluid, Bladder Habits & Hygiene

Fluid intake Target 1.5–2 L daily (dilutes bacteria + increases voiding frequency). Pale straw urine = adequate hydration. Spread throughout the day. Carry water bottle. Avoid excess caffeine and alcohol.
Voiding habits Void every 2–3 hours — avoid prolonged bladder stasis. Double-void technique (void, wait 30 seconds, void again — reduces residual urine). Post-coital voiding within 30 minutes (flushes periurethral bacteria mechanically — ~30% UTI reduction).
Bowel habit Constipation places faecal bacteria adjacent to the urethra. Daily bowel habit is protective. Increase fibre + fluid + activity. Treat constipation actively (lactulose, senna, Movicol).
Perineal hygiene Wipe front to back after defaecation. Warm water only for external washing (no soap — disrupts periurethral lactobacilli). Cotton underwear, changed daily.
Sexual activity and contraception Post-coital voiding within 30 minutes. Avoid spermicide-containing contraceptives (nonoxynol-9 disrupts normal vaginal flora → E. coli colonisation). Consider alternative to diaphragm if UTI is post-coital pattern.
Long-term catheter care ABU in long-term catheter = normal — do NOT treat unless symptomatic. Maintain closed drainage. Adequate hydration. Consider intermittent self-catheterisation (ISC) over indwelling if clinically feasible (lower UTI/sepsis risk).
D-mannose + cranberry (preventive) D-mannose 2 g OD: OTC, safe in pregnancy, equivalent to nitrofurantoin prophylaxis for E. coli UTI (Kranjcec RCT). Cranberry 36 mg PAC OD extract: modest but safe adjunct. Recommend before antibiotic prophylaxis.
Bladder diary Record voiding times, volumes, fluid intake, urgency, and symptoms × 3–5 days. Provides objective data for urology/urogynaecology referral and guides targeted advice.
Double-void technique and post-coital voiding are the two most high-yield, zero-cost lifestyle interventions for recurrent UTI: double-void reduces post-void residual in women with functional incomplete emptying (approximately 15–20% of recurrent UTI women have subtle voiding dysfunction), and post-coital voiding interrupts the mechanical bacterial inoculation that drives post-coital UTI. Both take 60 seconds to teach, have no adverse effects, and have evidence of clinical benefit. SGLT2 inhibitors increase UTI susceptibility through glycosuria — in diabetic women with recurrent UTI on SGLT2i, considering drug substitution or adding D-mannose/methenamine prophylaxis should be part of the management discussion.
9
Safety

Follow-Up & Monitoring

Self-start — 6-month review
Number of UTI episodes, organisms/sensitivities from cultures sent, antibiotic use pattern. If frequency increasing → prophylaxis or structural investigation. Ensure MSU samples are being sent for resistance surveillance. Document the arrangement.
Antibiotic prophylaxis monitoring
Nitrofurantoin continuous: annual CXR + LFT (pulmonary fibrosis risk >6 months use). Trimethoprim: annual FBC. Review at 6 months — still indicated? Has topical oestrogen been tried (post-menopausal)? Can prophylaxis be stopped?
Topical oestrogen monitoring
Annual review: UTI frequency reduced? Vaginal symptoms improved? Any postmenopausal spotting (→ pelvic USS to exclude endometrial pathology)? Topical oestrogen is long-term — do not stop after 3 months if effective.
Post-structural-investigation
Results reviewed and actioned. Structural abnormality treated before restarting prophylaxis. Flexible cystoscopy and urine cytology reports documented.
Same-day / 999
Fever + rigors + confusion + loin pain → urosepsis → 999 · Macroscopic haematuria without specific UTI symptoms → urgent urology same week (2WW) · Acute urinary retention → 999 / same-day urology
GP same week
UTI not responding at 48h → review MSU sensitivity result · New macroscopic haematuria during UTI treatment → 2WW urology (do not defer) · UTI frequency escalating despite optimised prevention → urology referral
Nitrofurantoin pulmonary fibrosis: estimated incidence approximately 1 in 5,000–10,000 patients on long-term continuous use. MHRA has issued repeated safety warnings. Clinical presentation: progressive breathlessness + dry cough + restrictive spirometry. Annual CXR + LFT monitoring is mandatory for patients on nitrofurantoin for >6 months. New respiratory symptoms in a patient on long-term nitrofurantoin = stop drug + chest imaging. Given this risk, methenamine hippurate is an increasingly attractive long-term alternative — no pulmonary or hepatic toxicity, no resistance selection. The 6-month prophylaxis review should also ask: has topical oestrogen been started (post-menopausal)? Has D-mannose or methenamine been tried? Are voiding habits optimised? Can antibiotics be stepped down or stopped?
Educational use only. Based on NICE NG112 UTI 2018/2022, NICE NG12 Suspected Cancer 2023, Raz and Stamm NEJM 1993 (topical oestrogen), Kranjcec et al. 2014 (D-mannose RCT), Bonkat et al. Cochrane 2022 (methenamine), PHE AMR data, BNF antibiotic dosing. Always adapt to individual patient context.